illumicell AI
Private Company
Funding information not available
Overview
illumicell AI is an early-stage, AI-driven diagnostics company operating out of the Harvard Pagliuca Life Lab. The company has developed a proprietary technology platform that uses AI to analyze cellular behavior, generating significantly more data than standard tests. Its initial focus areas are AI-powered semen analysis for fertility and immune cell activation readouts for immuno-oncology and autoimmune disease monitoring. The company raised a $2M pre-seed round in 2025 and is collaborating with Harvard on research studies.
Technology Platform
Proprietary AI/ML platform that analyzes live cellular behavior to generate high-density data signatures for diagnostics and monitoring. Applications include computer vision for semen analysis and functional assays for immune cell activation.
Opportunities
Risk Factors
Competitive Landscape
In fertility, competes with established manual lab services and new digital sperm analyzers (e.g., YO, Trak). In immune cell analysis, faces competition from large CROs (LabCorp, Q2 Solutions) and specialty labs adopting AI. In autoimmune monitoring, competes with large diagnostic companies and biopharma firms developing companion diagnostics.